Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology (PYXS) reported Q3 2025 results, highlighting ongoing R&D investment and a going concern warning. The company posted a net loss of $22.0 million for the quarter on zero revenue. Operating expenses were $23.5 million, including $17.8 million in research and development and $5.7 million in general and administrative costs.
As of September 30, 2025, Pyxis held $76.3 million in cash, cash equivalents, and short‑term investments, with total assets of $105.6 million and stockholders’ equity of $68.8 million. Net cash used in operating activities was $53.1 million for the nine months ended September 30, 2025. The company disclosed that current liquidity will not be sufficient to fund operations over the next 12 months, which raises substantial doubt about its ability to continue as a going concern.
Pipeline updates center on micvotabart pelidotin (MICVO). The FDA granted Fast Track Designation in February 2025 for recurrent/metastatic HNSCC monotherapy after platinum and anti‑PD-(L)1 therapy. Pyxis recognized $2.8 million in milestone revenue in the nine‑month period tied to Suvemcitug approval in China. Common shares outstanding were 62,264,215 as of October 31, 2025.
Pyxis Oncology (PYXS) furnished a Form 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The press release is provided as Exhibit 99.1.
The company indicated the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
GordonMD entities and Craig D. Gordon report a passive 13G stake in Pyxis Oncology (PYXS). The filing shows that GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon each report shared voting and dispositive power over 3,834,740 shares of Pyxis common stock, representing 6.2% of the class. All reported securities are owned by advisory clients of GordonMD Global Investments LP, with GordonMD Long Biased Master Fund LP identified as one advisory client that may hold more than 5%. The filing certifies the position is not intended to change or influence control of the issuer and includes a joint filing agreement and a control-person identification exhibit.
Pyxis Oncology (PYXS) is a clinical-stage oncology company focused on micvotabart pelidotin and reports significant historical losses with the expectation of continued losses while it advances development. The company has 62,018,135 shares outstanding as of June 30, 2025 and 190,000,000 shares authorized. It states a need for substantial additional capital and that failure to raise funds could delay or cut research, development or commercialization efforts. Preclinical and early clinical signals for micvotabart pelidotin are highlighted: robust tumor growth inhibition across patient-derived xenograft models, complete responses in multiple indications, tolerability in animal studies, and enhanced efficacy in combination with anti-PD-1. The company plans two ~20-patient expansion cohorts at 5.4 mg/kg IV Q3W with preliminary data expected in the second half of 2025 and the first half of 2026. Material business risks include regulatory, manufacturing, intellectual property and third-party reliance, and the company recorded no federal income tax provision for recent periods.
Pyxis Oncology, Inc. furnished an update on its business by issuing a press release with its financial results for the quarter ended June 30, 2025 and a broader corporate update. The company submitted this information in a current report so investors can access the press release, which is attached as Exhibit 99.1. The report clarifies that the press release and related information are being furnished, not filed, which limits certain legal liabilities and means the material is not automatically incorporated into other regulatory documents.
Pyxis Oncology (PYXS) Form 8-K – Item 8.01
On 31 Jul 2025 the company amended the ClinicalTrials.gov record for its first-in-human, open-label Phase 1 monotherapy trial of micvotabart pelidotin (MICVO, formerly PYX-201; NCT05720117). The revision increases the maximum number of participants that may be enrolled in both dose-escalation (Part 1) and dose-expansion (Part 2) cohorts. Management states the change is procedural and does not alter prior guidance on the expected head-and-neck squamous cell carcinoma (HNSCC) enrollment disclosed in the 15 May 2025 10-Q.
No safety, efficacy, or financial data were released, and all other disclosure items remain unchanged.
Pyxis Oncology, Inc. (Nasdaq: PYXS) filed an 8-K reporting the voting results of its June 18, 2025 virtual Annual Meeting of Stockholders.
Quorum: 43,996,450 shares (≈71% of the 61,947,665 shares outstanding as of the April 21, 2025 record date) were represented.
Proposal 1 – Election of Class I Directors (term through 2028):
- Dr. Santhosh Palani, Ph.D., CFA: 22,056,449 FOR / 7,314,363 WITHHELD / 14,625,638 broker non-votes
- Mr. Darren Cline: 22,028,914 FOR / 7,341,898 WITHHELD / 14,625,638 broker non-votes
- Dr. Rachel Humphrey, M.D.: 21,357,102 FOR / 8,013,710 WITHHELD / 14,625,638 broker non-votes
All nominees obtained simple-majority support and were elected.
Proposal 2 – Ratification of Independent Auditor: Ernst & Young LLP was re-appointed for fiscal 2025 with 43,733,259 FOR, 233,563 AGAINST and 29,628 ABSTAIN; no broker non-votes.
The filing contains no financial performance data, strategic updates or other material transactions. The matters voted on are routine governance items; both proposals passed comfortably, indicating continued shareholder support for the board slate and the external auditor.